A detailed history of Atlanta Consulting Group Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Atlanta Consulting Group Advisors, LLC holds 1,769 shares of VRTX stock, worth $873,249. This represents 0.2% of its overall portfolio holdings.

Number of Shares
1,769
Previous 438 303.88%
Holding current value
$873,249
Previous $205 Million 300.75%
% of portfolio
0.2%
Previous 0.04%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$460.0 - $505.78 $612,260 - $673,193
1,331 Added 303.88%
1,769 $823 Million
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $172,050 - $212,662
438 New
438 $205 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $127B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Atlanta Consulting Group Advisors, LLC Portfolio

Follow Atlanta Consulting Group Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atlanta Consulting Group Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atlanta Consulting Group Advisors, LLC with notifications on news.